Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
AQUATIC Trial: Validates Stopping ASA Improves Safety and Efficacy in CAD
Photo: <a href="https://depositphotos.com" target="_blank">Depositphotos</a>
Sep 22, 2025, 12:43

AQUATIC Trial: Validates Stopping ASA Improves Safety and Efficacy in CAD

Christopher Cannon, Editor in Chief, Harvard Health Publishing, shared a post on LinkedIn:

“Very important trial: AQUATIC: dropping ASA in CAD patients on anticoagulation improves both safety – and efficacy!

This validates the prior findings from the AFIRE trial.
For patients on anticoagulation, we need to look to stop the aspirin for long-term treatment.”

Read full article here.

AQUATIC Trial: Validates Stopping ASA Improves Safety and Efficacy in CAD

Title: Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation

Authors: Gilles Lemesle, Romain Didier, Philippe Gabriel Steg, Tabassome Simon, Gilles Montalescot, Nicolas Danchin, Christophe Bauters

Stay updated with Hemostasis Today.

AFIRE Trial Anticoagulation AQUATIC ASA Aspirin CAD Christophe Bauters Christopher Cannon Chronic Coronary Syndrome Gilles Lemesle Gilles Montalescot Headlines Health Hematology Hemostasis Hemostasis Today Medicine Nicolas Danchin Oral Anticoagulation Philippe Gabriel Steg Romain Didier Tabassome Simon
NewsFeed